Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combined agents for treatment of glaucoma

A technology of glaucoma and therapeutic agent, which is applied in the field of glaucoma preventive or therapeutic agent, and can solve problems such as insufficient glaucoma effect

Inactive Publication Date: 2005-05-18
SANKYO CO LTD
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Among the angiotensin II antagonists, only CGP-48933 has been clinically tested, and it has been reported that its effect on glaucoma is insufficient (Eur-J-Ophthalmol. 1997 Jan-March; 7(1); 35-9 ), and its development has not been carried out since

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined agents for treatment of glaucoma
  • Combined agents for treatment of glaucoma
  • Combined agents for treatment of glaucoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0071] New Zealand white rabbits weighing 2 to 3 kg were used to create an elevated intraocular pressure model according to the method of Kurihara et al. (Ophthalmic Pharmacology, pp. 62-64, Vol. 4, 1990), and the intraocular pressure-lowering effect of the test compound was examined.

[0072] That is, rabbits were general anesthetized with urethane, and intraocular pressure was measured with a tonometer (Alcon Applanation Pneumatonography: manufactured by Alcon Corporation). Then, after instilling the eyes of the rabbit with a local anesthetic, 0.1 ml of 5% sodium chloride water was injected into the vitreous through a 30 gauge injection needle. 30 minutes after the injection, after confirming the increase in intraocular pressure, 50 μl of the drug to be tested was instilled in the eye. Thereafter, intraocular pressure was measured at intervals of 30 minutes for 2 hours (single administration test).

[0073] In the combined drug administration test, after confirming the incr...

Embodiment 2

[0082] [Embodiment 2] Reduce intraocular pressure effect (2)

[0083] After the intraocular pressure was measured in New Zealand white rabbits (without anesthesia) weighing 2 to 3 kg using a tonometer (Alcon Applanation Pneumatonography: manufactured by Alcon Corporation), 50 μl of the test drug was instilled in the eyes. Thereafter, the intraocular pressure was measured at intervals of 1 hour for 4 hours (single administration test).

[0084] In the combined administration test, after confirming the intraocular pressure before instillation, instill 50 μl of the first test drug in the eye, 5 minutes later, instill the same amount of the second test drug, and then at intervals of 1 hour Measure intraocular pressure for 4 hours.

[0085] In addition, the same test drug as described in Example 1 was also used in this example.

[0086] When Compound A, which is an angiotensin II antagonist, is administered in combination with any of Compounds B, C, D, and E, an intraocular press...

Embodiment 3

[0087] [embodiment 3] reduce intraocular pressure test (3)

[0088] After the intraocular pressure was measured in the same manner as in Example 2, 150 μl of the test drug was instilled in the eyes, and 2 drops of the same amount of the test drug was used 5 minutes later. From this time, the intraocular pressure was measured 4 hours later, and the eye pressure was calculated using the following calculation formula: rate of change in pressure.

[0089] Intraocular pressure change rate (%) = [(intraocular pressure after instillation - intraocular pressure before instillation) / intraocular pressure before instillation] × 100

[0090] In addition, the same test drug as described in Example 1 was also used in the examples. The results are shown in Table 1 and Table 2 below.

[0091] Tested drug 1

[0092] Tested drug 1

[0093] As shown in Tables 1 and 2 above, a synergistic intraocular pressure-lowering effect was observed when the angiotensin II antagonist (c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a preventive or therapeutic agent for glaucoma, which contains an angiotensin II antagonist and dorzolamide or a pharmacologically acceptable salt thereof as active ingredients, and uses these active ingredients simultaneously, separately or sequentially, wherein the angiotensin II antagonist Factor II antagonists are compounds with the following general formula (I) or their pharmacologically acceptable salts, esters or other derivatives, wherein R1 is as defined in the claims.

Description

[0001] This application is a divisional case of a Chinese patent application (National Application No. 00816666.8, International Application No. PCT / JP00 / 08545) with an application date of December 1, 2000 and an invention titled "Adjuvant for Optophthalmology". Apply. technical field [0002] The present invention relates to a preventive or therapeutic agent for glaucoma having an excellent intraocular pressure-lowering effect. Background technique [0003] At present, as therapeutic agents for glaucoma, β-blockers (timolol maleate, carteolol, etc.), prostaglandin-type compounds (isopropyl unoprostone and latanoprost) and Carbonic dehydratase inhibitors (dorzolamide hydrochloride), in addition, α1 blockers (bunazosin hydrochloride), αβ blockers (nipredilol) are in clinical trials or application for approval. [0004] Regarding angiotensin II antagonists, it has been reported that they are useful as therapeutic agents for glaucoma (for example, EP 795326, EP 631780, WO 95 / 2...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/353A61K31/382A61K31/41A61K31/415A61K31/437A61K31/44A61K31/4439A61K31/495A61K31/535A61K31/5377A61K31/55A61K31/551A61K31/557A61K31/5575A61P27/06A61P43/00
CPCA61K31/41A61K31/415A61K31/44A61K31/535A61K31/55A61K31/557A61K45/06A61P27/06A61P43/00A61P9/12A61K31/38A61K2300/00A61K31/4439
Inventor 横山富久
Owner SANKYO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com